Eiger completes enrollment in phase 2 LIMT HDV study of pegylated interferon lambda
Eiger BioPharma announced completion of enrollment of the Phase 2 LIMT HDV Study, a monotherapy trial of pegylated interferon lambda 1a as potential treatment for chronic hepatitis D virus infection. LIMT HDV is designed to evaluate the safety, tolerability and efficacy of two dose levels. July 24, 2017